N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

Antibody–drug conjugates (ADCs) are targeted therapeutic agents that treat cancers by selective delivery of highly potent cytotoxic drugs to tumor cells via cancer-specific antibodies. However, their clinical benefit is limited by off-target toxicity and narrow therapeutic windows. To overcome these...

Full description

Bibliographic Details
Main Authors: Min Ji Ko, Daehae Song, Juhee Kim, Jae Yong Kim, Jaehyun Eom, Byungje Sung, Yong-Gyu Son, Young Min Kim, Sang Hoon Lee, Weon-Kyoo You, Jinwon Jung
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Antibody–drug conjugate
N-terminal conjugation
therapeutic window
toxicity
stability
trastuzumab
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.1914885

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2021.1914885

Similar Items